41 results about "Peptide structure" patented technology

The invention provides a hair care composition with oil control, hair loss prevention and repair effects and a preparation method of the hair care composition, and belongs to the technical field of hair care. The hair care composition comprises functional peptides such as myristoyl pentapeptide-4, palmitoyl tripeptide-1, acetyl tetrapeptide-3, hexapeptide-3, acetyl hexapeptide-8, palmitoyl tetrapeptide-7 and the like which are synergistically combined according to a specific proportion, and glycerin, water and a penetration enhancer are supplemented to form a basic system. By optimizing peptide structure modification, adding proportion and the steps of pH control, ultrasonic treatment and collaborative assembly in the preparation process, multi-path collaborative regulation and control of hair follicle activation, scalp inflammation inhibition and keratin synthesis enhancement are realized.

This invention relates to the field of bioinformatics processing and discloses a method and system for mining the structure-activity relationship (SMR) of porcine neurotrophic peptides based on sequence features. The method includes constructing an original sample index table and fusing multi-source production data, extracting peptide sequence features to generate a sequence feature matrix, constructing a sequence-process joint graph containing peptide nodes and process state nodes, training a structure-activity relationship graph neural network to mine SMR relationships, and deriving a process control decision table based on a process response sample set generated by the network, thereby achieving online optimization of the porcine neurotrophic peptide preparation process. This invention solves the problem of SMR mining caused by the separation of process parameters, sequence information, and activity data, achieving accurate characterization of the synergistic effect of sequence and process and reverse optimization of process parameters, thus improving the targeted enrichment efficiency and bioactivity retention level of target neurotrophic peptides.

This invention provides modified antimicrobial peptides, belonging to the field of antimicrobial peptide technology. The modified antimicrobial peptides include at least one of a first, second, third, fourth, fifth, and sixth antimicrobial peptide; the amino acid sequences of the first, second, third, fourth, fifth, and sixth antimicrobial peptides are shown sequentially as SEQ ID NO.1 to SEQ ID NO.6. Based on prevotellin-2, the modified antimicrobial peptides were obtained by reducing negatively charged amino acids, increasing positively charged amino acids, introducing hydrophobic amino acids, adjusting or deleting amino acid sequences, and optimizing the peptide structure. In vitro minimum inhibitory concentration (MIC) determination showed that, compared with the initial peptide, the modified antimicrobial peptides exhibited significantly enhanced antimicrobial activity against bacteria and fungi, and also showed significant bactericidal activity against clinically resistant bacteria.

Provided is a compound that includes a peptide structure represented by Formula (p1) or (p2). Also provided is a method for producing droplets using the compound. Xa is an amino acid residue having a hydrophilic side chain; Xb is an amino acid residue having a side chain represented by Formula (b1); Xc and Xd are each independently an amino acid residue or a glycine residue having a hydrophobic side chain; and n is an integer of 1 to 3. Ar1 is an aryl group or heteroaryl group which may have a substituent; and Ar2 is an arylene group or a heteroarylene group which may have a substituent.

This invention discloses a method for screening pancreatic lipase inhibitory peptides based on machine learning, relating to the fields of bioinformatics and food science. The method includes the following steps: dataset construction and three-dimensional peptide structure characterization, statistical-based feature screening, outlier removal based on a dual-model consensus mechanism, feature recursive elimination and physicochemical significance optimization, data augmentation based on Gaussian noise injection, and final prediction model construction. This invention effectively solves the problems of insufficient feature representation, high noise interference, and weak model generalization ability in existing screening methods through multi-dimensional feature characterization, rigorous outlier cleaning, and data augmentation strategies for small samples. It can quickly and accurately screen highly active pancreatic lipase inhibitory peptides from massive peptide sequences, providing an efficient computational tool for the development of functional foods and lipid-lowering drugs.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regular clustering interval short palindromic repeat (CRISPR). Specifically, the invention provides the application of the chromosome regulating peptide structural domain in improving the Cas protein editing efficiency, and the chromosome regulating peptide structural domain has a wide application prospect.

This disclosure provides peptides which have an affinity for the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK). In particular, the peptides are modified and derived from the sequence of the LD2 alpha helical domain of paxillin (e.g., LD2 peptides), the LD4 domain of paxillin (e.g., LD4 peptides), and CD8 peptides. These peptides are capable of blocking an interaction between paxillin and FAK, thereby inhibiting FAK activity related to FAK-paxillin interaction. The invention further provides uses for such peptides as therapeutics for the treatment of cancer and other diseases characterized with FAK activity and / or expression (e.g., fibrosis).

The present disclosure provides a method for biocatalytic production of a polycyclic peptide comprising providing a peptide sequence containing a recognition motif for a radical S-adenosylmethionine metallocnzyme (SAM enzyme), exposing the peptide sequence to an enzymatic reaction including catalysis under standard enzymatic reaction conditions with the radical SAM enzyme, and generating a further cyclized peptide by modifying a product of the enzymatic reaction chemically and / or via enzymes. The radical SAM enzyme catalysis generates macrocyclic modifications using unactivated carbon centers. The product of the enzymatic reaction may be modified using haloalkane- or haloacetyl-containing compounds, macrocyclases, or additional radical SAM enzymes. The peptide sequence may be altered at permissive sites to generate libraries of polycyclic peptide structures. The enzymatic reaction may occur at ambient temperature and pH under buffered aqueous conditions.

The present invention relates to a peptide structure specifically binding to carbonic anhydrase IX (CAIX), and a use thereof. The CAIX-binding peptide ligand of the present invention contains D-amino acids, and thus has high binding specificity to CAIX while being stable in the body, and a cyclic CAIX-binding peptide structure comprising same can bind to CAIX with high affinity in the body, and thus is effective in the diagnosis, prevention, suppression or treatment of diseases mediated by CAIX.

The application discloses a branched antibacterial peptide with double fatty acid tails and application thereof, and has the structure of taking Lys as a branched core, using Arg and Trp as two kinds of amino acids to replace the C-terminal of Lys, e -amino, α -amino, to obtain a branched peptide structure. The same length of saturated fatty acid tail chains are introduced into two N-terminal ends of the branched peptide structure to obtain the branched antibacterial peptide with double fatty acid tails, and the structure general formula is Cn-Z-K(Y-Cn)-X, which is marked as XYZn, wherein K is Lys, X, Y and Z are end-point amino acids Arg or Trp, Cn is a saturated fatty acid chain, and n is the number of carbon atoms of the fatty acid chain. The antibacterial peptide structure is novel, simple to synthesize, and has the advantages of broad-spectrum antibacterial activity, low toxicity and high safety in in-vitro antibacterial experiments and toxicity tests. Serum stability experiments show that the antibacterial peptide has excellent stability in mouse serum, and acute toxicity experiments show that the antibacterial peptide has high safety. Therefore, the antibacterial peptide has a good application prospect in preparation of clinical antibacterial drugs.

The invention discloses a mirror symmetry antibacterial oligopeptide rich in tryptophan and arginine and application of the mirror symmetry antibacterial oligopeptide. The antibacterial oligopeptide is obtained in the mode that tryptophan W and arginine R form a mirror symmetry peptide structure, then hydrophobic amino acid is modified at the two ends of the peptide sequence, and amidation is conducted on the C tail end; the structural general formula of the fluorescent probe is XRnWmRWmRnX-NH2, and the fluorescent probe is marked as RXm, or XWnRmWRmWnX-NH2, which is marked as WXm; or X (WR) 3WX-NH2, which is marked as RX; or X (RW) 3RX-NH2, which is marked as WX; wherein n = 0, 1 or 2, m = 1, 2 or 3, and n + m = 3. An in-vitro antibacterial activity experiment and a hemolysis experiment show that the antibacterial oligopeptide has relatively strong antibacterial activity on gram-positive bacteria and gram-negative bacteria, and meanwhile, the antibacterial oligopeptide has low hemolysis toxicity. The optimal antibacterial oligopeptide WF is obtained by calculating the therapeutic index, the corresponding full D-type amino acid sequence wf is synthesized, and the wf has high-efficiency antibacterial activity and low toxicity and also has high enzymolysis stability. Therefore, the antibacterial oligopeptide provided by the invention has a good application prospect in preparation of clinical antibacterial drugs.

The invention provides an oligonucleotide hydrogel micro-nano gene compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: firstly, designing C5ASO, and loading the C5ASO on a nano-carrier modified with HAP-1 peptide (targeting fibroblast-like synovial cells) and active ester; meanwhile, the porous HAMA hydrogel microspheres are prepared by utilizing a photo-crosslinking micro-fluidic technology; then, DBCO-TIMP and an azide group are respectively introduced into the liposome and the hydrogel microspheres through Michael addition and an amide coupling reaction, so that a micro-nano gene compound (C5ASO (at) HAP-CL-TIMP (at) HMs) is formed; in addition, the liposome and the hydrogel microspheres are efficiently compounded through click chemistry. The hydrogel micro-nano gene compound not only can efficiently load ASO lipidosome, but also can enhance the stability of a gene therapeutic agent in an in-vivo delivery process. Meanwhile, the MMP-9 response peptide structure in the RA articular cavity inflammation microenvironment can be accurately activated, so that continuous complement intervention is realized.

The invention belongs to the technical field of bioactive peptide preparation and food processing, and particularly relates to a giant salamander muscle peptide zinc chelate cranberry juice beverage and a preparation method thereof. Giant salamander peptide is extracted from giant salamander muscle, zinc ions are introduced for chelation, the giant salamander muscle peptide zinc chelate is prepared, finally, the giant salamander muscle peptide zinc chelate is compounded with cranberry juice, and then the giant salamander muscle peptide zinc chelate cranberry juice beverage is developed. Compared with a common fruit juice beverage or a single peptide functional beverage, the giant salamander muscle peptide zinc chelate cranberry juice beverage prepared by the preparation method disclosed by the invention is rich in nutritional value, unique in flavor and mouth feel, green and healthy in formula and wide in product application scene, the chelate is high in stability in a beverage system, and the retention rate of zinc is high after high-temperature sterilization and normal-temperature storage; and the product has stable quality in the shelf life, and is suitable for large-scale industrial production.

Provided herein are methods, devices, and kits for identifying glycosylated polypeptide biomarkers and signatures for progression of a disease or a condition, such as cancer or NASH, or and response of the disease or condition to a treatment. Also provided herein are: i) methods of generating and analyzing glycosylated polypeptide biomarkers, ii) methods of validating a model using glycosylated polypeptides for predicting the disease or condition or for making treatment recommendation, iii) systems and methods for implementing QC of a cohort of samples by analyzing peptide structure data for each sample using a machine learning model to generate a predicted age and / or sex associated for each sample. The quality control issue may include an error of mislabeled samples or an error from sample preparation, or a systemic measurement or an instrument error.

A method and system for diagnosing a subject with respect to a pancreatic cancer disease state. Peptide structure data corresponding to a biological sample obtained from the subject is received. The peptide structure data is analyzed using a supervised machine learning model to generate a disease indicator that indicates whether biological sample evidences the PC disease state based on at least 3 peptide structures selected from a group of peptide structures of Group I identified in Table 1 or of Group II of Table 8. The group of peptide structures in Table 1 or Table 8 comprises a group of peptide structures associated with the PC disease state. The group of peptide structures is listed in Table 1 with respect to relative significance to the disease indicator. A diagnosis output is generated based on the disease indicator

The objective is to provide a collagen production promoter that can efficiently promote collagen production. [Solution] A collagen production promoter containing a 3-hydroxypyridinium derivative represented by the following general formula (1) as an active ingredient. TIFF2026076348000020.tif49159 In the formula, A1 independently represents a hydroxyl group, an alkoxy group having 1 to 10 carbon atoms, a peptide structure having 1 to 100 amino acids linked at the N-terminus, a hydrogen atom, an amino group, or a hydrocarbon group having 1 to 10 carbon atoms, while A2 independently represents a hydrogen atom, a hydrocarbon group having 1 to 10 carbon atoms, an acyl group, or a peptide structure having 1 to 100 amino acids linked at the C-terminus.

This invention provides a receptor-binding domain polypeptide and its application in the preparation of fish lymphocystis virus inhibitors, belonging to the field of polypeptide technology. The amino acid sequence of the polypeptide is SEQ ID NO:1. This polypeptide can be used to prepare products for inhibiting LCDV infection, exerting its effect by blocking the binding of the virus to the VDAC2 receptor. In vitro experiments show that this polypeptide has significant concentration-dependent antiviral activity. Simultaneously, this polypeptide can also be used for VDAC2 labeling and localization analysis. The binding domain is highly conserved in various LCDV subtypes, showing broad application potential. The polypeptide of this invention has a simple structure, is easy to synthesize, and can be used to develop anti-LCDV drugs and related biological products.

The invention belongs to the field of polypeptides, and discloses an antibacterial peptide as well as a preparation method and application thereof. The antibacterial peptide is obtained by modifying the structure of the American oyster defensin derived peptide A4, and the antibacterial activity and stability of the original antibacterial peptide are further improved. Experiments prove that the antibacterial peptide disclosed by the invention has broad-spectrum antibacterial activity, and has good bacteriostatic activity on paratyphoid B and escherichia coli; pathogenic bacteria can be directly killed, and the effect is rapid; the hemolytic activity is low, the stability is relatively high, and the cytotoxicity is low. The antibacterial peptide provided by the invention is stable in preparation method and high in synthesis efficiency. The antibacterial peptide provided by the invention can be used as a therapeutic molecule for various common infections, and solves the increasingly serious problem of antibiotic drug resistance at present.

The invention belongs to the technical field of organic synthesis, and particularly discloses a TPA-AN and pyridine conjugate modified BODIPY fluorescent probe as well as a preparation method and application thereof. According to the near-infrared NO-BDP fluorescent probe and the preparation method thereof, the mose site of BODIPY is directionally modified by TPA-AN, pyridine is unilaterally modified on the alpha site of a BODIPY parent nucleus, an expanded conjugated system is constructed through Knoevenagel condensation, and the near-infrared NO-BDP fluorescent probe is obtained. Wherein the TPA-AN provides a strong electron supply effect and an intramolecular charge transfer (ICT) channel, and the stereo steric hindrance of a pyridine ring enables a molecular structure to be twisted into a non-planar configuration, so that pi-pi accumulation is reduced, and an ACQ effect is inhibited. Wherein a TPA-AN group and a BODIPY parent nucleus have a synergistic coordination effect, so that NO-BDP can sensitively recognize a phenylalanine dipeptide structural unit in the A beta 42 protein, and then sensitive recognition of the A beta protein is realized; and a pyridine group is introduced to realize electron conduction of NO-BDP, so that a D-pi-A structure is formed, more singlet oxygen is generated, a relatively strong antibacterial effect is shown, and photodynamic antibiosis is realized. Finally, multifunctional application is realized through the NO-BDP fluorescent probe.

The invention discloses a compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicine and medicinal chemistry. The structure of the compound is shown as a formula 1. The compound is a conjugate formed by covalent coupling of a natural active molecule, namely, kava piperonin A (FLA) and melanoma targeting peptide CPVYPLGP (the structure is as shown in a formula 2) through a disulfide bond, and can be expressed as CPV-SS-FLA. The compound disclosed by the invention can realize dual effects of'targeted delivery and GSH responsive release 'in a tumor microenvironment, and can inhibit proliferation of melanoma cells by triggering A375 cell apoptosis. The compound can be independently used as a melanoma targeted kavazinin A prodrug, can also be combined with other medicinal auxiliaries to be used as an anti-melanoma drug, and has an excellent anti-melanoma effect and relatively low toxic and side effects. Formula 1 and Formula 2.

The application relates to the field of biological information and discloses a toxic protein library construction method, device, equipment and medium. The method comprises the following steps: acquiring a common peptide structure corresponding to a confirmed toxic protein sequence, and constructing a target toxic protein core peptide set capable of covering a key functional domain of the confirmed toxic protein sequence based on function performance characteristic data and fluctuation trend characteristic data of the common peptide structure. The target toxic protein core peptide set is used for function screening of a to-be-recognized protein sequence in a function characteristic domain, so that an intermediate protein sequence needing to be verified whether it meets a toxicity characteristic is obtained, toxicity screening of the intermediate protein sequence in a toxicity characteristic domain is performed, and the intermediate protein sequence meeting the toxicity characteristic is determined as a target toxic protein sequence. Finally, a toxic protein database is constructed by using the target toxic protein sequence. Thus, a toxic protein library construction method with a wide coverage range which can discover new toxic proteins and detect low-abundance toxic proteins is realized through a two-level screening mode combining function screening and toxicity screening.

The present invention relates to peptide structures that specifically bind carbonic anhydrase IX (CAIX) and uses thereof. The CAIX-binding peptide ligand of the present invention contains a D-amino acid and thus has high binding specificity for CAIX while being stable in vivo, and the cyclic CAIX-binding peptide structure comprising the same can bind CAIX with high affinity in vivo, and thus is effective in the diagnosis, prevention, inhibition or treatment of diseases mediated by CAIX.

Systems and methods for predicting T-Cell receptor (TCR)-peptide interaction, including training a deep learning model for the prediction of TCR-peptide interaction by determining a multiple sequence alignment (MSA) for TCR-peptide pair sequences from a dataset of TCR-peptide pair sequences using a sequence analyzer, building TCR structures and peptide structures using the MSA and corresponding structures from a Protein Data Bank (PDB) using a MODELLER, and generating an extended TCR-peptide training dataset based on docking energy scores determined by docking peptides to TCRs using physical modeling based on the TCR structures and peptide structures built using the MODELLER. TCR-peptide pairs are classified and labeled as positive or negative pairs using pseudo-labels based on the docking energy scores, and the deep learning model is iteratively retrained based on the extended TCR-peptide training dataset and the pseudo-labels until convergence.

The invention discloses a polypeptide for activating BACE1 lactylation and application of the polypeptide, and belongs to the technical field of biological medicine. The polypeptide for activating BACE1 lactylation is a combined body TAT-B300P formed by a polypeptide taken from a functional segment near a BACE1 protein K300 site and a cell penetrating peptide TAT, and the sequence of the TAT-B300P is TAT-NLRLPKKVFEAAV. The polypeptide drug provided by the invention is introduced into a cell-penetrating peptide structure, has good cell permeability, is beneficial to play a role in a central nervous system, enables a drug delivery mode to be more flexible, can act on a BACE1K300 key site in a targeting manner and regulate and control the functional state of the BACE1K300 key site, has relatively high targeting and specificity, and is beneficial to reducing abnormal activation of an APP beta-lysis pathway.

This invention relates to the field of peptide preparation technology, specifically disclosing an immune-enhancing polypeptide derived from *Houttuynia cordata*, its preparation method, and its applications. The amino acid sequence of the polypeptide is shown in SEQ ID NO.1. This invention obtains the polypeptide through enzymatic extraction, chromatographic separation and purification, activity tracking screening, and mass spectrometry identification. Zebrafish experiments have confirmed that this polypeptide can significantly increase the activities of alkaline phosphatase, acid phosphatase, superoxide dismutase, and lysozyme content, exhibiting excellent immune-enhancing activity. In a *Shigella spp.* challenge experiment, the survival rate of zebrafish in the 200 mg / kg dose group reached 90.00%, far exceeding the 6.67% of the model control group. The *Houttuynia cordata*-derived immune-enhancing polypeptide of this invention has a well-defined structure and significant activity, and can be safely and efficiently used to enhance the immunity of aquatic animals and resist *Shigella spp.* infection, leaving no residue and unlikely to induce drug resistance, showing broad application prospects.

The present invention relates to a peptide construct that specifically binds to fibroblast activation protein-α (FAP-α) and use thereof. The FAP-α peptide construct of the present invention comprises a peptide ligand that includes one or more D-amino acids and specifically binds to FAP-α, thereby exhibiting excellent stability in vivo and being effective in targeting FAP-α, and has a structure of chemical formula 1 including a substituted or unsubstituted pyrrolidinyl group linked to the peptide ligand, thereby exhibiting high binding affinity for FAP-α. Therefore, the FAP-α peptide construct is useful for diagnosing, preventing, suppressing or treating FAP-α-overexpressing diseases.

The invention provides a PAD4 inhibitor and synovial membrane targeting peptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The PAD4 inhibitor and synovial membrane targeting peptide conjugate provided by the invention has a synovial membrane targeting peptide structure, and can enter and be accumulated in joint tissues through systemic circulation after administration. The linker used in the invention has a chemical bond which can be split under an acidic or oxidation condition, and can quickly release ZT-5 in a responsive manner under low pH and high oxidation conditions in an arthritis inflammation microenvironment, so that the effect of resisting rheumatoid arthritis is achieved. Meanwhile, the ZT-5 can be enriched into the facet joint cavity by utilizing the excessively proliferated synovial tissue, so that the bioavailability of the ZT-5 is improved, the administration frequency is reduced, and the defect of poor pharmacokinetic performance of a PAD4 inhibitor based on a Cl-amidine structure is overcome.

The application belongs to the technical field of polypeptide cyclization, and specifically provides a cyclic peptide construction method based on thiol-alkene photo-click chemistry, comprising the following steps: S1, designing a polypeptide sequence containing multiple cysteines; S2, reducing disulfide bonds in the polypeptide through a thiol reducing agent; S3, under ultraviolet light irradiation, performing thiol-alkene photo-click chemistry reaction on the reduced polypeptide, a crosslinking agent and a photoinitiator to form a cyclic peptide structure. The method uses ultraviolet light to excite the addition reaction of thiol and alkene, generates stable thioether bonds, constructs a cyclic peptide structure, has high selectivity and high efficiency, and is performed under mild conditions without using a metal catalyst. The method is applied to the construction of a phage display cyclic peptide library, and has wide application potential in the construction of a bicyclic peptide library. The obtained cyclic peptide has significantly enhanced stability, and provides an effective tool for screening high-quality cyclic peptide ligands that specifically bind to a target.

The invention aims to provide a polypeptide with an immunomodulatory effect, namely a hexapeptide which has an immunomodulatory effect and is separated from bursa of Fabricius, and the amino acid sequence of the hexapeptide is RNKDVY. The bursa of Fabricius hexapeptide is obtained from a bursa of Fabricius extract through a separation method, and the bursa of Fabricius hexapeptide is simple in structure, free of toxic and side effects and extremely weak in immunogenicity. Meanwhile, the production of cell factors and the proliferation of lymphocytes can be regulated, and the cellular immune response can be promoted. The method can be separated and extracted from the bursa of Fabricius and can also be chemically synthesized, the cost is low, and mass production can be realized. In addition, differentiation of the B cells is adjusted in a dose-dependent mode, and the method has wide application prospects such as application in the aspects of immunoregulation, treatment and the like.

The invention relates to the technical field of food and bioactive peptide preparation, in particular to an ion-modified cubilose peptide compound for improving bone mineral density and promoting growth and development as well as a preparation method and application of the ion-modified cubilose peptide compound. The cubilose peptide compound comprises cubilose peptide modified by metal ions, and the metal ion loading capacity of the cubilose peptide compound is 15-25%. According to the ion-modified cubilose peptide compound disclosed by the invention, through metal ion modification, the binding capacity of cubilose peptide to metal ions is improved, so that the ion-modified cubilose peptide compound has antioxidant activity and biological activity for promoting osteoblast differentiation, and the nutritional function characteristics of a product are improved. Aiming at the particularity of the cubilose peptide structure, the metal ion modification method provided by the invention can improve the modification stability and batch consistency, improve the metal ion loading amount, and reduce the influence on the cubilose peptide nutritional ingredients. The preparation method is simple and convenient to operate and suitable for large-scale production and application.